Efficacy of Single Dose Rasburicase (1.5 mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome

Rasburicase is a recombinant urate oxidase enzyme approved for use in tumor lysis syndrome (TLS) and it acts by reducing serum uric acid levels. Using rasburicase at the recommended dose of 0.2 mg/kg/day for 5 days is expensive and it is not known whether this extended schedule is clinically benefic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Indian J Hematol Blood Transfus
Hauptverfasser: Philips, Ashwin, Radhakrishnan, Venkatraman, Ganesan, Prasanth, Ganesan, T. S., Ramamurthy, Jaikumar, Dhanushkodi, Manikandan, Sagar, T. G.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer India 2018
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6186245/
https://ncbi.nlm.nih.gov/pubmed/30369730
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12288-018-0938-9
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge